News 02.11.17

Anglo-Dutch research teams awarded Eurostars funding for a €1.1M project to develop a synthetic matrix for 3D organoid cell culture

Researchers at Maastricht University, Noviocell BV (based at Pivot Park) and Cell Guidance Systems Ltd are collaborating on an EU funded Eurostars project to develop fully-defined matrices for the 3D culture of organoids.

Read more
News 02.11.17

US FDA APPROVES ASTRAZENECA’S CALQUENCE® (acalabrutinib) FOR ADULT PATIENTS WITH PREVIOUSLY-TREATED MANTLE CELL LYMPHOMA

AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to CALQUENCE® (acalabrutinib).

Read more
News 19.10.17

Novel synergistic combinations identified by unbiased high-throughput screening

A high-throughput screening approach to identify novel synergistic drug combinations has been launched by NTRC.

Read more
News 19.10.17

Mirjam Mol neemt afscheid van Pivot Park

Mirjam Mol-Arts neemt afscheid als directeur van Pivot Park en het Pivot Park Screening Centre.

Read more
News 17.10.17

New at Pivot Park – ChardonPharma

Chardon Pharma recently moved into their laboratory in Pivot Park's Chesbrough Building.

Read more
News 17.10.17

New at Pivot Park – NanoServe

NanoServe has opened the doors of its office and laboratory at Pivot Park.

Read more
News 25.09.17

NTRC announces approval of key TTK kinase inhibitor patent

NTRC today announced that the USPTO has granted patent protection for a key patent for its TTK kinase inhibitor programme.

Read more
News 14.09.17

Start-up Talent Transmitter opent zijn deuren op het Pivot Park in Oss

Per 18 september vestigt Talent Transmitter zich op het Pivot Park in Oss.

Read more
News 13.09.17

New at Pivot Park – GenTac

GenTac, joining the Pivot Park community in September, provides the tactical and strategic tools of transnational communications to industry, institutions, agencies, publications and nonprofit organizations worldwide.

Read more